- Home
- TRS vs LTGO Comparison
TRS vs LTGO Comparison
Compare TRS & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRS | LTGO |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2004 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TRS | LTGO |
|---|---|---|
| Price | $38.44 | $14.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $45.00 | ★ $52.25 |
| AVG Volume (30 Days) | 237.9K | ★ 296.9K |
| Earning Date | 10-29-2026 | 11-19-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 21.96 | N/A |
| Revenue | ★ $645,720,000.00 | N/A |
| Revenue This Year | $4.95 | N/A |
| Revenue Next Year | $2.79 | N/A |
| P/E Ratio | $1.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.43 | $15.27 |
| 52 Week High | $45.43 | $25.93 |
Technical Indicators
Market Signals| Indicator | TRS | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 27.58 |
| Support Level | $38.15 | N/A |
| Resistance Level | $39.91 | $25.17 |
| Average True Range (ATR) | 0.84 | 1.51 |
| MACD | -0.01 | -0.54 |
| Stochastic Oscillator | 27.71 | 1.62 |
Price Performance
Historical ComparisonAbout TRS TriMas Corporation
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.